Diabetic nephropathy: Causes and managements

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 1, 2013, Pages 57-64

  Tripathi, Yamini B ^a   Yadav, Durgavati ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Chronic kidney disease; Diabetic nephropathy; Herbals; Patented drugs

Indexed keywords

A2A ADENOSINE RECEPTOR AGONIST; ALISKIREN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BIGUANIDE DERIVATIVE; BIOLOGICAL PRODUCT; CYCLOOXYGENASE 1 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; GALACTOSYLCERAMIDE; GLUCAGON; HEMOGLOBIN A1C; HERBACEOUS AGENT; IRON CHELATOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITAZOXANIDE; ORNIPLABIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROPIONYLCARNITINE; PROTEIN KINASE C; PYRIDOXAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHEIN; RUBOXISTAURIN; SITAGLIPTIN; SULFONYLUREA; SULODEXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

BLOOD PRESSURE; CATARACT; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DIET RESTRICTION; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG TARGETING; ENZYME ACTIVATION; GLOMERULUS FILTRATION RATE; GLUCAGON RELEASE; HEADACHE; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; INFECTION; MESANGIUM CELL; MICROALBUMINURIA; NEPHRON; NONHUMAN; OXIDATIVE STRESS; PATENT; PATHOGENESIS; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; URINALYSIS; URINARY EXCRETION;

EID: 84873151631     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221413804660971     Document Type: Review

References (80)

1. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: A high-risk state for diabetes development. Lancet 2012; 379(9833):2279-90.
2. Amutha A, Datta M, Unnikrishnan R, Anjana RM, Mohan V. Clinical profile and complications of childhood-and adolescentonset type-2 diabetes seen at a diabetes center in south India. Diabetes Technol Ther 2012; 14(6):497-504.
3. Raman R, Gupta A, Krishna S, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type-2 diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complications 2012; 26(2):123-8.
4. Parameswaran S, Geda SB, Rathi M, Kohli HS, Gupta KL, Sakhuja V, et al. Referral pattern of patients with end-stage renal disease at a public sector hospital and its impact on outcome. Natl Med J India 2011; 24(4):208-13.
5. Debnath S, Thameem F, Alves T, Nolen J, Al-Shahrouri H, Bansal S, et al. Diabetic nephropathy among Mexican Americans. Clin Nephrol 2012; 77(4):332-44.
6. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14:1358-73.
7. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008; 88(11): 1322-35.
8. Corwin Elizabeth J. Handbook of Pathophysiology, 3rd Edition, Lippincott Williams & Wilkins 2008.
9. Aird WC. Phenotypic heterogeneity of the endothelium: I. structure, function, and mechanisms. Circulation Res 2007; 100:158-73.
10. Reitsma S, Slaaf DW, Hans V, van Zandvoort MAMJ, oude Egbrink MGA. The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch-Eur J Physiol 2007; 454:345-59.
11. Pavenstädt H, Kriz W, Kretzler M. Cell Biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
12. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59:251-87.
13. Banday AA, Fazili FR, Lokhandwala MF. Oxidative stress causes renal dopamine d1 receptor dysfunction and hypertension via mechanisms that involve nuclear factor-b and protein kinase C. J Am Soc Nephrol 2007;18: 1446-1457.
14. Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type-2 diabetes and preserved kidney function. CJASN 2012; 7(3): 401-8.
15. Tang WH, Cheng WT, Kravtsov GM, Tong XY, Hou XY, Chung SK, et al. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol 2010; 299(3): C643-53.
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
17. Anderson SA, Tsilibary EC, Charonis AS. Nonenzymatic glycosylation induced modifications of intact bovine kidney tubular basement membrane. J Clin Invest 1993; 92:3045-52.
18. van Dijk, Berl T. Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord 2004; 5: 237-48.
19. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, et al. Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation. Diabetes 2000; 49: 1239-48.
20. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38:1077-81.
21. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21: 480-5.
22. D'Elia JA, Roshan B, Maski M, Weinrauch LA. Manifestation of renal disease in obesity: Pathophysiology of obesity-related dysfunction of the kidney. Int J Nephrol Renovasc Dis 2009; 2: 39-49.
23. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116:85-97.
24. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18(12):945-59.
25. Jim B, Ghanta M, Qipo A, Fan Y, Chuang PY, Cohen HW, et al. Dysregulated nephrin in diabetic nephropathy of type-2 diabetes: A cross sectional study. PLoS One 2012;7(5):e36041.
26. Hirowatari, Y., Hara, K., Takahashi, H. Diagnostic marker for vascular endothelial injury. US6485753 (2002).
27. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, et al. T-1095, an inhibitor of renal Na-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48:1794-800.
28. Barnett AH. Linagliptin: A novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther 2011; 28(6):447-59.
29. Brown DX, Choudhury M, Evans M. Linagliptin as add-on therapy for type 2 diabetes - an overview. Drugs Today (Barc) 2012; 48(10):645-54.
30. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia 2012; 55(8):2256-66.
31. Satirapoj B, Supasyndh O, Chaiprasert A, Ruangkanchanasetr P, Kanjanakul I, Phulsuksombuti D, et al. Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology 2010; 15(2):253-258.
32. Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type-2 diabetes. Diabetes Ther 2011; 2(3): 133-45.
33. Drel VR, Pacher P, Stevens MJ, Obrosova IG. Aldose reductase inhibition counteracts nitrosative stress and poly (ADP-ribose) polymerase activation in diabetic rat kidney and high-glucoseexposed human mesangial cells. Free Radic Biol Med 2006; 40(8):1454-65.
34. Chatzopoulou M, Alexiou P, Kotsampasakou E, Demopoulos VJ. Novel aldose reductase inhibitors: A patent survey (2006-present). Expert Opin Ther Pat 2012; 22(11):1303-23.
35. Yokkaichi, J.P., Toyama, J.P., Yokkaichi, J.P. Preventive, relieving or therapeutic composition for diabetes mellitus and/ or diabetic nephropathy. WO2006082643 (2006).
36. Chennasamudram SP, Kudugunti S, Boreddy PR, Moridani MY, Vasylyeva TL. Renoprotective effects of (+)-catechin in streptozotocin-induced diabetic rat model. Nutr Res 2012; 32(5):347-56.
37. Scindia YM, Deshmukh US, Bagavant H. Mesangial pathology in glomerular disease: Targets for therapeutic intervention. Adv Drug Deliv Rev 2010; 62: 1337-43.
38. Zhou L, An XF, Teng SC, Liu JS, Shang WB, Zhang AH, et al. Pretreatment with the total flavone glycosides of Flos Abelmoschus manihot and hyperoside prevents glomerular podocyte apoptosis in streptozotocin-induced diabetic nephropathy. J Med Food 2012;15(5):461-8.
39. Wang K, Wu YG, Su J, Zhang JJ, Zhang P, Qi XM. Total glucosides of paeony regulates JAK2/STAT3 activation and macrophage proliferation in diabetic rat kidneys. Am J Chin Med 2012; 40(3):521-36.
40. Liu H, Xu H, Shen C, Wu C. Effect of the best compatibility of components in Corni Fructus on WT1 expression in glomerular podocytes of type 2 diabetic rats with early nephropathy. Am J Chin Med 2012; 40(3):537-49.
41. Zhu, Q., Shi, X., Tang, D., Zheng, Z., He, B., Duan T., Gu, F., Cheng, H., Huang, X., Huang, Y., Wang, R. Pharmaceutical composition for diabetic nephropathy and its preparation and application. US20100261787 (2010).
42. Li, L. Drug for treating diabetic nephrosis. US6197818 (2001).
43. Chaurasia JK, Tripathi YB. Chemical characterization of various fractions of leaves of Cinnamomumtamala Linn toward their antioxidant, hypoglycemic, and anti-inflammatory property. Immunopharmacol Immunotoxicol 2011; 33(3): 466-72.
44. Ranjana CJK, Nagwani S, Tripathi YB. Antioxidant potential of standardized leave's extract of Annonasquamosa Linn.: In vitro study. J Pharm Biomed Res 2012; 2(1): 172-9.
45. Tripathi YB, Chaturvedi P. Assessment of endocrine response of Inula racemosa in relation to glucose homeostasis in rats. Indian J Exp Biol 1995; 33(9):686-9.
46. Chaturvedi P, Tripathi P, Pandey S, Singh U, Tripathi YB. Effect of Saussurea lappa alcoholic extract on different endocrine glands in relation to glucose metabolism in the rat. Indian J Exp Biol 1995; 33(9):686-9.
47. Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, et al. Effect of addition of silymarin to reninangiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012; [Epub ahead of print].
48. Qiu W, Zhou Y, Jiang L, Fang L, Chen L, Su W, et al. Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice. PLoS One 2012; 7(7):e41391.
49. Egidio, M., Gianfranco, T. Use of glycosaminoglycans in treatment of diabetic nephropathy and diabetic neuropathy. US005236910 (1993).
50. Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ. Binding affinities of vascular endothelial growth factor (VEGF) for heparinderived oligosaccharides. Biosci Rep 2012; 32(1):71-81.
51. Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14(10):946-52.
52. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4:444-52.
53. Prockop, D.J., Lee R.H., Seo M.J. Methods for treating diabetes. US20120027729 (2012).
54. Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012; 7(9):1394-400.
55. Mason RM. Fell-Muir lecture: connective tissue growth factor (CCN2) - a pernicious and pleiotropic player in the development of kidney fibrosis. Int J Exp Pathol 2012; doi: 10.1111/j.1365-2613.2012.00845.x.
56. Hirowatari, Y., Hara, K., Takahashi, H. Method for assessing arteriosclerosis and diabetic nephropathy. US20120122242 (2012).
57. Spieker E, Wagner-Redeker W, Dingemanse J. Validated LCMS/ MS method for the quantitative determination of the glucosylceramide synthaseinhibitormiglustat in mouse plasma and human plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal 2012; 59:123-9.
58. Shukla A, Radin NS. Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, and the synergistic action of an inhibitor of microsomal monooxygenase. J Lipid Res 1991; 32(4):713-22.
59. Montes R, Díez J, Hermida J. Activated protein C: Reasons to believe. J Thromb Haemost 2012; doi: 10.1111/j.1538-7836.2012.04847.x.
60. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13(11):1349-58.
61. Miraghajani MS, Esmaillzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. Diabetes Care 2012; [Epub ahead of print].
62. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289(4): 645-59.
63. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005; 62:1671-81.
64. Wu D, Wen W, Qi CL, Zhao RX, Lü JH, Zhong CY, et al. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 2012; 19(8-9):712-8.
65. Hasumi, K., Yagasaki, K. Pharmaceutical composition for treatment or prevention of nephritis and manufacturing methode thereof. US20090270476 (2009).
66. He LJ, Liang M, Hou FF, Guo ZJ, Xie D, Zhang X. Ethanol extraction of Picrorhiza scrophulariiflora prevents renal injury in experimental diabetes via anti-inflammation action. J Endocrinol 2009; 200(3):347-55.
67. Chadban SJ, Tesch GH, Foti R, Atkins RC, Nikolic-Paterson DJ. Interleukin-10 is a mesangial cell growth factor in vitro and in vivo. Lab Invest 1997; 76(5):619-27.
68. Tsai SJ, Huang CS, Mong MC, Kam WY, Huang HY, Yin MC. Anti-inflammatory and antifibrotic effects of naringenin in diabetic mice. J Agric Food Chem 2012; 60(1):514-21.
69. Soetikno V, Watanabe K, Sari FR, Harima M, Thandavarayan RA, Veeraveedu PT, et al. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats. Mol Nutr Food Res 2011; 55(11):1655-65.
70. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006;290(6):E1339-46.
71. Yamabe N, Yokozawa T, Oya T, Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006; 319(1):228-36.
72. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab 2011; 8:35.
73. Das J, Sil PC. Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Amino Acids 2012; [Epub ahead of print].
74. Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008; 57(2):460-9.
75. Danis RP, Sheetz MJ, Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother 2009; 10(17):2913-25.
76. Qian M, Liu M, Eaaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": Implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun1998; 250: 385-9.
77. Darwin, J. Methods for treating diabetes. WO2007127408 (2007).
78. Okusa M.D., Linden, J.M., Macdonald, T.L. Awad, A.S. Agonist of A2A adenisine receptors for treatment of diabetic nephropathy. US20050261236 (2005).
79. Stasi MA, Scioli MG, Arcuri G, Mattera GG, Lombardo K, Marcellini M, et al. Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol 2010; 30(3):426-35.
80. Davidson EP, Coppey LJ, Holmes A, Yorek MA. Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats. Eur J Pharmacol 2012; 677(1-3):180-7.